Age related changes in fractional elimination pathways for drugs: assessing the impact of variable ontogeny on metabolic drug-drug interactions.
about
Physiologically Based Pharmacokinetic Predictions of Tramadol Exposure Throughout Pediatric Life: an Analysis of the Different Clearance Contributors with Emphasis on CYP2D6 Maturation.Database of Optimized Proteomic Quantitative Methods for Human Drug Disposition-Related Proteins for Applications in Physiologically Based Pharmacokinetic Modeling.How Does In Vivo Biliary Elimination of Drugs Change with Age? Evidence from In Vitro and Clinical Data Using a Systems Pharmacology Approach.Changes in individual drug-independent system parameters during virtual paediatric pharmacokinetic trials: introducing time-varying physiology into a paediatric PBPK modelThe impact of age and CYP2C9 and VKORC1 variants on stable warfarin dose in the paediatric population.Clinical pharmacology in neonates: small size, huge variabilityHuman Ontogeny of Drug Transporters: Review and Recommendations of the Pediatric Transporter Working GroupA physiologically based pharmacokinetic drug-disease model to predict carvedilol exposure in adult and paediatric heart failure patients by incorporating pathophysiological changes in hepatic and renal blood flowsThe Promises of Quantitative Proteomics in Precision MedicineTailored tools to improve pharmacotherapy in infants.Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies.Ontogeny of Hepatic Drug Transporters and Relevance to Drugs Used in Pediatrics.Physiologically Based Pharmacokinetic Modeling in Pediatric Oncology Drug Development.Causes and Consequences of Variability in Drug Transporter Activity in Pediatric Drug Therapy.Strategies for Determining Correct Cytochrome P450 Contributions in Hepatic Clearance Predictions: In Vitro-In Vivo Extrapolation as Modelling Approach and Tramadol as Proof-of Concept Compound.Physiologically based pharmacokinetic model for 6-mercpatopurine: exploring the role of genetic polymorphism in TPMT enzyme activity.Editor's Highlight: Neonatal Activation of the Xenobiotic-Sensors PXR and CAR Results in Acute and Persistent Down-regulation of PPARα-Signaling in Mouse Liver.Humans Vary, So Cardiac Models Should Account for That Too!Predicting Stereoselective Disposition of Carvedilol in Adult and Pediatric Chronic Heart Failure Patients by Incorporating Pathophysiological Changes in Organ Blood Flows-A Physiologically Based Pharmacokinetic Approach.Pharmacokinetics and drug-drug interactions of lopinavir/ritonavir administered with first and second-line antituberculosis drugs in HIV-infected children treated for multidrug-resistant tuberculosis.A framework and case studies for evaluation of enzyme ontogeny in children's health risk evaluation.Semi-Mechanistic Model for Predicting the Dosing Rate in Children and Neonates for Drugs Mainly Eliminated by Cytochrome Metabolism.Pediatric Cytochrome P450 Activity Alterations in Nonalcoholic Steatohepatitis.Response to: “Prediction of Voriconazole Non-Linear Pharmacokinetics Using a Paediatric Physiologically Based Pharmacokinetic Modelling Approach”
P2860
Q27312881-5171E8D8-D4F1-4E6C-83A3-177AF5A64F83Q30490654-238FDB40-79AA-4E1D-BCE6-90FD727AF60AQ31043972-C228DAF3-18F3-4168-B9B5-2DAC88CF942EQ33574126-559E4DE9-AEBF-4D35-B0D1-FBD6837A075BQ33707218-56B42EB8-E839-4D07-A5B5-0B751409D978Q33950874-E645D1EB-6F11-405C-A358-B128A4816459Q35667919-9646882F-0ED2-4C68-B1D9-4AC232598D9CQ36025902-D975F319-BD93-4983-8151-4B3B2537C390Q37647264-1932A63A-A48A-4EBD-9127-523188F26C28Q38222870-7688B0A5-9112-4356-9944-5B9A47779E25Q38420688-D836B1CE-FB8D-43CB-8EB0-467B4797C0C6Q38682009-5E779747-5C25-4360-98EB-1826737AF771Q38758820-86DCE18E-C303-4051-B012-3890542DBAC2Q38888350-FBDE50A9-A544-4272-B571-462DE5B92368Q39673902-F432494D-AC0E-446F-B80E-F2CC0F7982E0Q41368460-2DA57808-2460-44E9-B4FA-A677D10896A9Q41658107-23F07640-B9E4-44CF-A096-B44C967B8EB4Q42077295-036A6FEA-CC08-48B5-8BC2-3FD3EE4E35CDQ43456116-9605C052-6955-42BA-9D7E-3B5174BDD519Q46895816-1BDB6229-F2FD-4D53-B7D9-622D0E159898Q47254105-08A94678-A282-4376-A3A0-944C8973305CQ47826980-0A0904BF-A76E-4444-B25E-5935EDC94F4FQ47847406-BD086878-C4BC-42D5-BA87-DF43E5664732Q57730438-D6A820A2-CD3B-44CA-AB41-69171F6D00C6
P2860
Age related changes in fractional elimination pathways for drugs: assessing the impact of variable ontogeny on metabolic drug-drug interactions.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Age related changes in fractio ...... abolic drug-drug interactions.
@en
Age related changes in fractio ...... abolic drug-drug interactions.
@nl
type
label
Age related changes in fractio ...... abolic drug-drug interactions.
@en
Age related changes in fractio ...... abolic drug-drug interactions.
@nl
prefLabel
Age related changes in fractio ...... abolic drug-drug interactions.
@en
Age related changes in fractio ...... abolic drug-drug interactions.
@nl
P2093
P2860
P356
P1476
Age related changes in fractio ...... abolic drug-drug interactions.
@en
P2093
Amin Rostami-Hodjegan
Farzaneh Salem
J Steven Leeder
Trevor N Johnson
Zoe E Barter
P2860
P304
P356
10.1002/JCPH.100
P577
2013-05-30T00:00:00Z